Citius Oncology Inc (CTOR)

Who cares they gave away 20 million to manufacturing buds, not a good company.

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic MalignanciesJune 1, 2026 7:00 AM
PR Newswire (US) Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patients20.5 months of median progression-free survival observed among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21) Responses were observed in patients previously treated with immune checkpoint inhibitors, including a 33% objective response rate in patients with relapsed or refractory endometrial cancerCRANFORD, N.J., June 1, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today highlighted Phase 1 clinical data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in patients with recurrent or refractory gynecologic malignancies. The poster presentation (Abstract #2564) was presented by investigators from the University of Pittsburgh Medical Center (UPMC) Magee-Womens Hospital. "LYMPHIR's ability to transiently deplete immunosuppressive regulatory T-cells may help address immune resistance in the tumor microenvironment and enhance the effect of checkpoint inhibitors. The encouraging clinical signals and tolerability profile observed in this study support continued clinical evaluation of this "chemo-free" immunomodulatory approach, especially in tumors where resistance to checkpoint inhibitors remains a significant challenge," said Dr. Myron S. Czuczman, Chief Medical Officer of Citius Oncology.The open-label Phase 1 study evaluated LYMPHIR in combination with pembrolizumab in 25 heavily pre-treated patients (21 evaluable for efficacy) with recurrent or metastatic solid tumors, primarily gynecologic malignancies. Enrolled patients had received a median of five prior therapies, and more than half had previously received anti-PD-1 or PD-L1 therapy.Key Efficacy and Safety findings presented at ASCO included:24% Overall Response Rate (ORR) among the 21 efficacy-evaluable patients (5 partial responses).Median duration of response (mDOR) had not yet been reached because only 1 of the 5 partial responders had progressed at the time of analysis (80% of PRs were continuing to experience clinical benefit). The current duration of response times (time since PR was achieved) were 4.2-35 months with a median of 21.1 months.33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors, including one patient with an ongoing response greater than three years.48% of efficacy-evaluable patients (10 of 21) achieved clinical benefit, defined as complete response (CR), partial response (PR), or durable stable disease lasting at least six months:Median progression-free survival (mPFS) of 20.5 months (95% CI: 6.5 – NA) among the 10 patients who achieved clinical benefit; overall mPFS across all 21 efficacy-evaluable patients was 5.8 months (95% CI: 2.2 – NA);5 patients had a PFS of > 20 months including 1 patient with > 30 months PFS;Of the 24/25 pts evaluable for dose limiting toxicities (DLTs), only 1 case of reversible Gr 3 capillary leak syndrome (CLS) was observed at the highest dose level. A maximum tolerated dose was not achieved.16 serious adverse events were observed in seven patients treated at the highest dose level. No new safety signals or grade 3 or greater immune-related adverse events were observed.Dr. Alexander Olawaiye, a professor and one of the gynecologic cancer researchers at UPMC Magee-Womens Hospital and lead investigator of the study, added, "Patients with recurrent gynecologic malignancies who progress following immunotherapy often have limited treatment options. The clinical activity observed with denileukin diftitox-cxdl plus pembrolizumab, including durable responses and prolonged disease control in heavily pre-treated patients, is notable. Given the lack of effective salvage treatments for these patients, especially those that have failed prior immune-checkpoint inhibition, the novel combination of LYMPHIR plus pembrolizumab provides a potential viable therapeutic option. Importantly, the safety profile observed was manageable in this heavily pre-treated population, supporting continued evaluation in larger studies."Ongoing translational studies are evaluating the impact of the combination on regulatory T-cells, immune effector cells, and the tumor microenvironment to help identify potential biomarkers in order to optimize future development strategies. A Phase 2 expansion study is being planned to further evaluate the combination in gynecologic cancers, including less heavily pre-treated and prior immunotherapy-exposed patient populations.About the StudyThis open-label, dose-escalation, investigator-initiated Phase?1 study (NCT05200559), led by Dr. Alexander B Olawaiye at UPMC Magee-Womens Hospital, enrolled 25 patients with recurrent or metastatic solid tumors who had received at least one prior line of therapy. LYMPHIR was administered intravenously on Days?1–3 of each 21-day cycle at escalating doses (3, 6, 9, and 12 mcg/kg), along with pembrolizumab (200?mg IV) on Day?1. Patients who completed eight cycles of combination therapy were continued on pembrolizumab monotherapy until disease progression. Citius Oncology provided study drug and financial support to the investigator-initiated study; the study was designed, conducted, and analyzed by the UPMC investigators.Important note on investigational use: The use of LYMPHIR in this study was investigational and outside of its FDA-approved indication of relapsed or refractory Stage I–III cutaneous T-cell lymphoma. LYMPHIR is not approved by the FDA for the treatment of gynecologic malignancies or any solid tumor, and the safety and efficacy of LYMPHIR in this setting have not been established. This Phase 1 study was not designed or powered to evaluate clinical efficacy, and no conclusions can be drawn regarding comparative effectiveness or long-term outcomes. Early-stage clinical data may not be predictive of results from larger or later-stage studies.About Gynecologic CancersRecurrent or metastatic ovarian and endometrial cancers are two of the most common gynecologic malignancies in the United States. Endometrial cancer is the most frequently diagnosed gynecologic cancer, with an estimated 70,000 new endometrial cancer cases expected in the United States in 20261, while ovarian cancer remains the deadliest with approximately 12,700 deaths per year (51.6%) and approximately 20,000 new diagnoses each year in the United States2. These cancers are often detected at advanced stages, and although many patients initially respond to platinum-based chemotherapy, most experience relapse and develop resistance. Survival rates in the recurrent setting remain poor, and responses to current immunotherapies such as PD-1 inhibitors are limited, highlighting a significant unmet need for novel treatment approaches. LYMPHIR's transient depletion of regulatory T-cells in combination with anti-PD-1 checkpoint inhibition may potentially enhance host anti-tumor immune responses and help overcome immunotherapy resistance in these difficult-to-treat tumors.About LYMPHIR (denileukin diftitox-cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl-associated anti-tumor activity is achieved via a direct cytocidal action on IL-2R-expressing tumors and depletion of host immunosuppressive regulatory T lymphocytes (Tregs).In 2021, reformulated denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize reformulated denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with Nasdaq's continued listing standards; our ability to obtain, perform under and maintain third party agreements and relationships, including obtaining a new bulk drug substance supplier; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability to secure and maintain strategic partnerships and expand international access to LYMPHIR; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.REFERENCES:American Cancer Society. Cancer Facts & Figures 2026 (projected). Atlanta: American Cancer Society; 2026. https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.htmlNational Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Uterine and Ovarian Cancer. https://seer.cancer.gov/statfacts/html/ovary.htmlLYMPHIR (denileukin diftitox-cxdl)INDICATIONLYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.IMPORTANT SAFETY INFORMATION BOXED WARNING: CAPILLARY LEAK SYNDROMECapillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.WARNINGS AND PRECAUTIONS Capillary Leak SyndromeLYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin

Buy at .0001, not signing contracts that protect share holders. Siphoning money to 3rd party. Didnt have shareholders consent. Lots wrong with this.

Threw away over 20 million of stockholders equity. Just siphoned off millions to the wind.

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 4:30 PM
PR Newswire (US) $5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 million in debt and equity financingAdvanced patient access with payer coverage near 100% of commercial lives and 83% of LYMPHIR target accounts on formulary or in review CRANFORD, N.J., May 15, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported business and financial results for the fiscal second quarter ended March 31, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR)."The first half of fiscal 2026 demonstrated meaningful commercial progress at our majority-owned subsidiary Citius Oncology. In the four months of commercial sales since the December 2025 launch of LYMPHIR, Citius Oncology generated $5.6 million in net revenue at approximately 80% gross margins, advanced 83% of target accounts to formulary inclusion or active review, and secured payer coverage representing near 100% of covered commercial lives with no reimbursement denials reported to date. Importantly, major academic centers have begun to transition patients to local community infusion centers for treatment, a critical next phase of commercial scaling. These results reflect our efforts to build a durable patient access foundation upon which to drive growth," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharma and Citius Oncology."Subsequent to quarter end, Citius Oncology secured up to $36.5 million in combined debt and equity financing through its senior secured credit facility with Avenue Capital and the exercise of outstanding warrants, complemented by Citius Pharma's $5 million registered direct offering. Together, these proceeds are expected to fund Citius Pharma's activities as well as the completion of the LYMPHIR commercial field force buildout by mid-summer. This will support expanded physician engagement and broader market penetration, positioning Citius Oncology to accelerate growth as the launch matures. We believe Citius Oncology maintains sufficient inventory to support anticipated commercial demand, as well as additional demand outside the U.S., as we begin to see orders for product through our global distribution partners.""Moreover, we are encouraged by positive preliminary topline Phase 1 data from two investigator-initiated combination studies, with pembrolizumab and prior to CAR-T therapy, which reinforce LYMPHIR's potential as a platform asset in combination regimens. At the Citius Pharma level, we also remain focused on advancing Mino-Lok and Halo-Lido with the FDA and on disciplined execution of our mission to bring first-in-class therapies to patients," concluded Mazur.Fiscal Second Quarter 2026 Business Highlights and Subsequent DevelopmentsReported key commercial metrics of LYMPHIR launch:83% of target accounts had added or were actively progressing LYMPHIR through formulary review;Secured near 100% of covered commercial lives; no reimbursement denials or prior authorization barriers reported;Initial accounts placing repeat orders;Patients beginning to transition from larger academic cancer centers to community infusion centers;Announced initial shipment of LYMPHIR to Europe on April 29, 2026 through Uniphar, a leading international healthcare services company, with LYMPHIR being made available to eligible patients through Named Patient Programs (NPPs) in accordance with local regulations across 19 markets in Southern Europe, the Middle East, and additional European territories;Announced positive topline results from two investigator-initiated Phase 1 studies, including:LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies;LYMPHIR administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with positive topline safety and efficacy results; and,Continued FDA engagement on Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and on Halo-Lido (CITI-002), a topical formulation for hemorrhoids.Fiscal Second Quarter 2026 Financial Highlights and Subsequent EventsCash and cash equivalents of $4.6 million as of March 31, 2026;Citius Pharma closed a $5 million registered direct offering in April 2026;Citius Oncology secured up to $36.5 million in financing subsequent to quarter end, consisting of:$11.5 million in gross proceeds received May 5, 2026 from the exercise of certain outstanding warrants;a loan agreement of up to $25 million from Avenue Capital Group, with $10 million in gross proceeds funded at close on May 6, 2026, and up to $15 million available in subsequent tranches pending certain revenue and liquidity milestones; and,Citius Pharma and Citius Oncology collectively expect to have sufficient funds to continue operations through November 2026;Net product revenues of $1.7 million for the three months ended March 31, 2026, compared to no revenue in the three months ended March 31, 2025, and $5.6 million for the six months ended March 31, 2026, compared to no revenue in the six months ended March 31, 2025; quarter over quarter decline reflects larger initial orders from specialty distributors at launch in the first quarter;Gross profit of $1.3 million for the three months ended March 31, 2026, and $4.5 million for the six months ended March 31, 2026; approximately 80% in both periods, reflecting continued commercial progress since the December 2025 launch of LYMPHIR;R&D expenses of $1.6 million for the three months ended March 31, 2026, compared to $3.8 million for the three months ended March 31, 2025; and $3.2 million for the six months ended March 31, 2026, compared to $5.9 million for the six months ended March 31, 2025. The decrease in both periods primarily reflects reduced clinical development activity, as the prior-year periods included costs for a pre-license inspection batch of LYMPHIR previously manufactured;G&A expenses of $26.4 million for the three months ended March 31, 2026, compared to $4.8 million for the three months ended March 31, 2025, primarily driven by a $19.7 million one-time CMO contract cancellation charge. G&A expenses were $32.1 million for the six months ended March 31, 2026, compared to $10.2 million for the six months ended March 31, 2025;Stock-based compensation expense was $3.8 million for the three months ended March 31, 2026, compared to $2.7 million for the three months ended March 31, 2025. For the six months ended March 31, 2026, stock-based compensation was $8.1 million, compared to $5.2 million for the six months ended March 31, 2025;Recognized a gain of $3.8 million from the sale of New Jersey state net operating losses under the New Jersey Technology Business Tax Certificate Transfer Program; and,Net loss applicable to common stockholders of $21.2 million, or $(0.95) per share, for the three months ended March 31, 2026, compared to $10.9 million, or $(1.27) per share, for the three months ended March 31, 2025; and $29.5 million, or $(1.34) per share, for the six months ended March 31, 2026, compared to $20.7 million, or $(2.58) per share, for the six months ended March 31, 2025.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.About Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 71% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharmaceuticals. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier; our ability to regain compliance with Nasdaq's continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025 and as amended on January 28, 2026. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.Investor Contact:
Ilanit Allen
ir @crsrs-6677 x113Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com – Financial Tables Follow – CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)


March 31,

September 30,


2026

2025
ASSETS





Current Assets:





Cash and cash equivalents
$4,590,174

$4,252,290
Accounts receivable, net of allowances

1,079,055


-
Inventory

22,659,590


22,286,693
Prepaid expenses

3,356,882


1,395,490
Total Current Assets

31,685,701


27,934,473









Operating lease right-of-use asset, net

794,518


818,694









Deposits

38,062


38,062
In-process research and development, net of accumulated amortization

90,506,250


92,800,000
Deferred financing costs

169,252


-
Goodwill

9,346,796


9,346,796
Total Other Assets

100,060,360


102,184,858









Total Assets
$132,540,579

$130,938,025









LIABILITIES AND STOCKHOLDERS' EQUITY







Current Liabilities:







Accounts payable
$9,453,803

$13,693,692
License payable

17,650,000


22,650,000
Accrued expenses

24,138,264


4,190,253
Accrued compensation

3,602,007


3,292,447
Note payable

-


1,000,000
Operating lease liability

171,495


88,348
Total Current Liabilities

55,015,569


44,914,740









Deferred tax liability

7,803,790


7,770,760
Operating lease liability – noncurrent

636,667


724,925
Total Liabilities

63,456,026


53,410,425









Commitments and Contingencies
















Stockholders' Equity:







Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued
and outstanding

-


-
Common stock - $0.001 par value; 250,000,000 shares authorized; 22,376,427 and
18,067,744 shares issued and outstanding at March 31, 2026 and September 30,
2025, respectively

22,376


18,068
Additional paid-in capital

329,775,214


306,336,239
Accumulated deficit

(268,256,054)


(238,804,129)
Total Citius Pharmaceuticals, Inc. Stockholders' Equity

61,541,536


67,550,178
Non-controlling interest

7,543,017


9,977,422
Total Equity

69,084,553


77,527,600









Total Liabilities and Equity
$132,540,579

$130,938,025
 CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025(Unaudited)


Three Months Ended

Six Months Ended


March 31,

March 31,

March 31,

March 31,


2026

2025

2026

2025
Revenues
$1,667,298

$—

$5,611,409

$—
Cost of revenues

(328,878)


—


(1,118,086)


—
Gross Profit

1,338,420


—


4,493,323


—

















Operating Expenses















Research and development

1,633,518


3,766,525


3,233,237


5,893,563
Amortization of in-process research and development

1,720,312


—


2,293,750


—
General and administrative

26,391,101


4,792,122


32,111,828


10,179,874
Stock-based compensation – general and administrative

3,788,275


2,702,031


8,068,502


5,226,855
Total Operating Expenses

33,533,206


11,260.678


45,707,317


21,300,292

















Operating Loss

(32,194,786)


(11,260,678)


(41,213,994)


(21,300,292)

















Other Income (Expense)















Interest income

53,584


13,413


98,681


36,021
Gain on sale of New Jersey net operating losses

3,833,277


—


3,833,277


—
Interest expense

(33,031)


—


(188,569)


—
Total Other Income, Net

3,853,830


13,413


3,743,389


36,021

















Loss before Income Taxes

(28,340,956)


(11,247,265)


(37,470,605)


(21,264,271)
Income tax expense (benefit)

(231,210)


264,240


33,030


528,480

















Net Loss

(28,109,746)


(11,511,505)


(37,503,635)


(21,792,751)
Net loss attributable to non-controlling interest

6,878,606


595,000


8,051,710


1,108,000

















Net loss applicable to common stockholders
$(21,231,140)

$(10,916,505)

$(29,451,925)

$(20,684,751)

















Net Loss Per Share - Basic and Diluted
$(0.95)

$(1.27)

$(1.34)

$(2.58)

















Weighted Average Common Shares Outstanding















Basic and diluted (includes pre-funded warrants from the
October 2025 offering)

22,376,427


8,581,207


21,931,009


8,029,834
 CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE SIX MONTHS ENDED MARCH 31, 2026 AND 2025(Unaudited)


2026

2025
Cash Flows From Operating Activities:





Net loss
$(37,503,635)

$(21,792,751)
Adjustments to reconcile net loss to net cash used in operating activities:







Stock-based compensation expense

8,068,502


5,226,855
Issuance of common stock for services

107,510


-
Issuance of common stock warrant

68,597


-
Amortization of in-process research and development

2,293,750


-
Amortization (accretion) of operating lease right-of-use asset

24,176


110,845
Deferred income tax expense

33,030


528,480
Changes in operating assets and liabilities:







Accounts receivable, net of allowances

(1,079,055)


-
Inventory

(372,897)


(7,070,487)
Prepaid expenses

(1,961,392)


(308,791)
Accounts payable

(4,239,889)


4,441,023
Accrued expenses

19,948,011


8,762,217
Accrued compensation

309,560


955,048
Operating lease liability

(5,111)


(117,767)
Net Cash Used In Operating Activities

(14,308,843)


(9,265,328)









Cash Flows From Investing Activities:







License fee payments

(5,000,000)


—
Net Cash Used in Investing Activities

(5,000,000)


—









Cash Flows From Financing Activities:







Repayment of note payable

(1,000,000)


—
Deferred financing costs

(169,252)


—
Proceeds from exercise of Citius Oncology pre-funded warrants

818


—
Net proceeds from common stock offerings

20,815,161


6,039,858
Net Cash Provided By Financing Activities

19,646,727


6,039,858









Net Change in Cash and Cash Equivalents

337,884


(3,225,470)
Cash and Cash Equivalents - Beginning of Period

4,252,290


3,251,880
Cash and Cash Equivalents - End of Period
$4,590,174

$26,410
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:







Interest paid
$105,310

$—
Operating lease right-of-use asset and liability recorded
$—

$786,697
  View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2026-financial-results-and-provides-business-update-302773890.htmlSOURCE Citius Pharmaceuticals, Inc. Original: Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 4:30 PM
PR Newswire (US) $5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progresses
Up to $36.5 million in debt and equity capital secured
Broad payer coverage established with no reimbursement denials
83% of target accounts on formulary or in reviewCRANFORD, N.J., May 15, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal second quarter ended March 31, 2026, and provided a business update. "LYMPHIR's commercial launch gives us confidence in the trajectory ahead. In the first six months of fiscal 2026, which includes only four months of commercial sales since LYMPHIR's December 2025 launch, we generated $5.6 million in net revenue at gross margins of approximately 80%. This reflects initial orders by distributors during the first quarter, and subsequent reorders during the second quarter as we begin to see increased institutional demand for the therapy. As leading medical centers continue to add LYMPHIR to formulary and we build out our sales force, we believe we are moving through the expected transition from initial channel fill to sustained treatment-driven demand. We have achieved strong institutional penetration for a newly launched specialty therapy, with 83% of our target accounts having added LYMPHIR or actively progressing it through formulary review. Payer coverage has expanded to near 100% of covered commercial lives, with no reimbursement denials reported to date," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma."With market access efforts underway, our focus is on establishing LYMPHIR's position in the CTCL treatment journey. The financing we secured, subsequent to quarter end, is the catalyst that provides us with resources to complete the buildout of our commercial field force. We expect to have the full commercial team deployed by mid-summer. We have ample finished goods and work-in-process inventory on hand to support anticipated commercial demand for the foreseeable future. A fully staffed sales organization, reinforced by broad market access and sufficient inventory to support anticipated demand, is how we plan to drive continued momentum. The fundamentals of a successful specialty pharmaceutical launch, which include strong formulary and payer access, a funded commercial buildout, and healthy margins, are all moving in the right direction," added Mazur."Building on the commercial foundation we are establishing in the U.S., we have initiated our first European shipment as part of the international distribution agreements we have in place across 19 markets in Southern Europe, the Middle East, and additional Western and Eastern European territories. At the same time, we continue to strengthen LYMPHIR's long-term value proposition through our support of clinical evidence generation. Recent preliminary topline Phase 1 investigator-initiated trial data reinforce the immuno-oncology rationale for LYMPHIR in combination settings, including its T-regulatory cell (Treg) depletion mechanism, and we look forward to additional data readouts in the future. Together, these execution milestones and data-driven catalysts reinforce our view that LYMPHIR can be developed beyond U.S. CTCL as a platform asset in combination regimens. We look forward to sharing continued positive momentum as LYMPHIR establishes itself as a meaningful new option in the treatment of relapsed or refractory CTCL, and we remain confident in its broader long-term commercial potential," concluded Mazur.Fiscal Second Quarter 2026 Business Highlights and Subsequent DevelopmentsAdvanced formularly inclusion with 83% of target accounts having added or actively progressing LYMPHIR through formulary review;Secured near 100% of covered commercial lives; no reimbursement denials or prior authorization barriers reported;Initiated community infusion center penetration, with patients beginning to transition from larger academic cancer centers, a critical next phase of commercial scaling;Initiated shipment of LYMPHIR to Europe, with LYMPHIR being made available through Named Patient Programs (NPPs) per local regulations;Continued deployment of a proprietary AI-powered machine learning platform to support targeted physician engagement and efficient penetration of the highly concentrated CTCL prescriber base;Recruited and trained initial field sales team, with expanded field force recruitment underway;Announced positive topline results from two investigator-initiated Phase 1 studies evaluating LYMPHIR in combination settings, including:Phase 1 trial of LYMPHIR in combination with pembrolizumab (KEYTRUDA®) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies;Phase 1 trial of LYMPHIR administered prior to CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with positive topline safety and efficacy results; and,Initiated evaluation of new bulk drug substance (BDS) suppliers with letter of intent with a new contract manufacturing organization (CMO) expected by the end of June 2026; $22.7 million of finished goods and work-in-process inventory as of March 31, 2026 to support anticipated commercial demand during the transition;Fiscal Second Quarter 2026 Financial Highlights and Subsequent DevelopmentsCash and cash equivalents of $2.6 million as of March 31, 2026, prior to the up to $36.5 million concurrent debt and equity financings that closed in early May 2026;Secured up to $36.5 million in combined financing subsequent to quarter end, consisting of:a senior secured term loan facility of up to $25 million from Avenue Venture Opportunities Fund II, L.P. (Avenue Capital Group), with $10 million funded at close on May 6, 2026, up to $7 million available beginning October 1, 2026 subject to revenue and liquidity milestones, and up to $8 million available beginning January 1, 2027 subject to additional revenue milestones; and,approximately $11.5 million in gross proceeds received May 5, 2026 from the exercise of certain outstanding warrants; and,Net product revenues of $1.7 million for the three months ended March 31, 2026, compared to no revenue for the three months ended March 31, 2025; and $5.6 million for the six months ended March 31, 2026, compared to no revenue for the six months ended March 31, 2025;Gross profit of $1.3 million (80% margin) for the three months ended March 31, 2026, and $4.5 million (80% margin) for the six months ended March 31, 2026;R&D expenses of $1.1 million for the three months ended March 31, 2026, compared to $3.1 million for the three months ended March 31, 2025; and $2.1 million for the six months ended March 31, 2026, compared to $4.4 million for the six months ended March 31, 2025;G&A expenses of $23.6 million for the three months ended March 31, 2026, compared to $2.2 million for the three months ended March 31, 2025, primarily driven by the $19.7 million one-time CMO contract cancellation charge. G&A expenses were $26.5 million for the six months ended March 31, 2026, compared to $5.6 million for the six months ended March 31, 2025;Stock-based compensation expense of $3.5 million for the three months ended March 31, 2026, compared to $2.1 million for the three months ended March 31, 2025; and $7.5 million for the six months ended March 31, 2026, compared to $3.9 million for the six months ended March 31, 2025;Recognized a gain of $1.76 million from the sale of New Jersey state net operating losses under the New Jersey Technology Business Tax Certificate Transfer Program; and,Net loss of $26.6 million for the three months ended March 31, 2026, compared to a net loss of $7.7 million for the three months ended March 31, 2025; and a net loss of $32.1 million for the six months ended March 31, 2026, compared to a net loss of $14.4 million for the six months ended March 31, 2025.Fiscal Second Quarter 2026 Financial Results:LiquidityAs of March 31, 2026, the Company had $2.6 million in cash and cash equivalents.Subsequent to quarter end, on May 5, 2026, the Company received approximately $11.5 million in gross proceeds from the exercise of certain outstanding warrants, and on May 6, 2026, the Company funded $10 million in gross proceeds under the first tranche of a senior secured term loan facility with Avenue Capital Group providing access to up to $25 million in total gross proceeds.We plan to continue to partially rely on funding from Citius Pharma, to raise capital through equity and debt financings, and to generate revenue from sales of LYMPHIR. We also have retained Jefferies LLC as our exclusive financial advisor in evaluating strategic alternatives aimed at maximizing shareholder value.After giving effect to the May 2026 equity and debt financings, we expect that Citius Oncology and Citius Pharma collectively will have sufficient funds to continue operations through November 2026.   Net RevenueNet product revenues were $1.7 million for the three months ended March 31, 2026, compared to no revenue for the three months ended March 31, 2025. For the six months ended March 31, 2026, net product revenues were $5.6 million, compared to no revenue for the six months ended March 31, 2025.The Company launched LYMPHIR in December 2025. The quarterly decrease in product revenues is primarily attributable to larger initial orders in the quarter ended December 31, 2025, as US distributors established their initial inventories. We believe that revenues will increase in the future as LYMPHIR gains market acceptance and initial accounts continue placing repeat orders. At the end of April 2026, we announced an initial shipment of LYMPHIR to Europe.Research and Development (R&D) ExpensesR&D expenses were $1.1 million for the three months ended March 31, 2026, compared to $3.1 million for the three months ended March 31, 2025, a decrease of $2.0 million. For the six months ended March 31, 2026, R&D expenses were $2.1 million, compared to $4.4 million for the six months ended March 31, 2025, a decrease of $2.3 million. The decrease in both periods primarily reflects reduced clinical development activity, as the prior-year periods included costs for a pre-license inspection batch of LYMPHIR previously manufactured.General and Administrative (G&A) ExpensesG&A expenses were $23.6 million for the three months ended March 31, 2026, compared to $2.2 million for the three months ended March 31, 2025, an increase of $21.4 million. For the six months ended March 31, 2026, G&A expenses were $26.5 million, compared to $5.5 million for the six months ended March 31, 2025, an increase of $21.9 million. The increase in both periods was primarily driven by a $19.7 million one-time contract cancellation charge related to the CMO termination recognized in March 2026.Stock-based Compensation ExpenseStock-based compensation expense was $3.5 million for the three months ended March 31, 2026, compared to $2.1 million for the three months ended March 31, 2025. For the six months ended March 31, 2026, stock-based compensation was $7.5 million, compared to $3.9 million for the six months ended March 31, 2025.Net LossNet loss was $26.6 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025, an increase of $18.9 million. For the six months ended March 31, 2026, net loss was $32.1 million, compared to $14.4 million for the six months ended March 31, 2025, an increase of $17.7 million. The increase in net loss for the three-month period was primarily attributable to the $19.7 million CMO contract cancellation charge, partially offset by $1.7 million in LYMPHIR revenues and the $1.76 million gain on the sale of New Jersey net operating losses.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.About Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 71% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier; our ability to regain compliance with Nasdaq's continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.Investor Contact:
Ilanit Allen
ir @crsrs-6677 x113Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com – Financial Tables Follow –CITIUS ONCOLOGY, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)


March 31,
2026

September 30,
2025
Current Assets:





Cash and cash equivalents
$2,632,634

$3,924,908
Accounts receivable, net of allowances

1,079,055


—
Inventory

22,659,590


22,286,693
Prepaid expenses

3,052,387


1,331,280
Total Current Assets

29,423,666


27,542,881









Other Assets:







In-process research and development, net of accumulated amortization

71,106,250


73,400,000
Deferred financing costs

169,252


—
Total Other Assets

71,275,502


73,400,000









Total Assets
$100,699,168

$100,942,881
LIABILITIES AND STOCKHOLDERS' EQUITY







Current Liabilities:







Accounts payable
$8,883,239

$13,234,684
License payable

17,650,000


22,650,000
Accrued expenses

24,057,573


4,093,124
Due to related party

8,221,486


9,513,771
Total Current Liabilities

58,812,298


49,491,579









Deferred tax liability

2,817,990


2,784,960
Note payable to related party

3,800,111


3,800,111
Total Liabilities

65,430,399


56,076,650
Stockholders' Equity:







Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued
     and outstanding

—


—
Common stock - $0.0001 par value; 400,000,000 shares authorized at March 31,
     2026 and September 30, 2025; 92,981,204 and 83,513,442 shares issued and
     outstanding at March 31, 2026 and September 30, 2025, respectively

9,298


8,351
Additional paid-in capital

131,443,191


108,897,836
Accumulated deficit

(96,183,720)


(64,039,956)
Total Stockholders' Equity

35,268,769


44,866,231
Total Liabilities and Stockholders' Equity
$100,699,168

$100,942,881
 CITIUS ONCOLOGY, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025 (Unaudited)


Three Months Ended

Six Months Ended


March 31,

March 31,

March 31,

March 31,


2026

2025

2026

2025
Revenues
$1,667,298

$—

$5,611,409

$—
Cost of revenues

(328,878)


—


(1,118,086)


—
Gross Profit

1,338,420


—


4,493,323


—

















Operating Expenses















Research and development

1,079,354


3,139,413


2,097,706


4,403,921
Amortization of in-process research and development

1,720,312


—


2,293,750


—
General and administrative

23,625,639


2,243,327


26,484,978


5,565,306
Stock-based compensation – general and administrative

3,526,710


2,088,572


7,482,760


3,897,050
Total Operating Expenses

29,952,015


7,471,312


38,359,194


13,866,277

















Operating Loss

(28,613,595)


(7,471,312)


(33,865,871)


(13,866,277)

















Other Income (Expense)















Interest income

43,721


—


72,009


—
Gain on sale of New Jersey net operating losses

1,762,000


—


1,762,000


—
Interest expense

(33,031)


—


(78,872)


—
Total Other Income

1,772,690


—


1,755,137


—

















Loss before Income Taxes

(26,840,905)


(7,471,312)


(32,110,734)


(13,866,277)
Income tax expense (benefit)

(231,210)


264,240


33,030


528,480

















Net Loss
$(26,609,695)

$(7,735,552)

$(32,143,764)

$(14,394,757)

















Net Loss Per Share - Basic and Diluted
$(0.27)

$(0.11)

$(0.34)

$(0.20)

















Weighted Average Common Shares Outstanding















Basic and diluted (includes pre-funded warrants from the
     December 2025 offering)

100,027,204


71,552,402


93,657,757


71,552,402
 CITIUS ONCOLOGY, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE SIX MONTHS ENDED MARCH 31, 2026 AND 2025(Unaudited)


2026

2025
Cash Flows From Operating Activities:





Net loss
$(32,143,764)

$(14,394,757)
Adjustments to reconcile net loss to net cash provided by operating activities:







Stock-based compensation expense

7,482,760


3,897,050
Amortization of in-process research and development

2,293,750


-
Deferred income tax expense

33,030


528,480
Changes in operating assets and liabilities:







Accounts receivable, net of allowances

(1,079,055)


-
Inventory

(372,897)


(7,070,487)
Prepaid expenses

(1,721,107)


-
Accounts payable

(4,351,445)


3,964,688
Accrued expenses

19,964,449


8,722,168
Due to related party

(1,292,285)


4,352,858
Net Cash (Used In) Provided By Operating Activities

(11,186,564)


-
Cash Flows From Investing Activities







    License payments

(5,000,000)


-
Net Cash Used In Investing Activities

(5,000,000)


-
Cash Flows From Financing Activities







    Deferred financing costs

(169,252)


-
    Net proceeds from issuance of common stock

15,063,542


-
Net Cash Provided by Financing Activities

14,894,290


-
Net Change in Cash and Cash Equivalents

(1,292,274)


-
Cash and Cash Equivalents – Beginning of Period

3,924,908


112
Cash and Cash Equivalents – End of Period
$2,632,634

$112
Supplemental Disclosures of Cash Flow Information and Non-cash
     Transactions:







Interest Paid
$14,460

$-
  View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-second-quarter-2026-financial-results-and-provides-business-update-302773892.htmlSOURCE Citius Oncology, Inc. Original: Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® CommercializationMay 5, 2026 8:00 PM
PR Newswire (US) Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain conditionsGross proceeds of approximately $11.5 million secured by a concurrent exercise of certain outstanding warrants held by single healthcare-focused institutional investor Financings to support ongoing commercial execution while preserving flexibility for future growth initiativesCRANFORD, N.J., May 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today announced that it has entered into a senior secured term loan credit facility (the "Credit Facility") with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group ("Avenue"), providing for up to $25 million in capital to support the ongoing commercialization of LYMPHIR® (denileukin diftitox-cxdl), approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, and has also entered into a definitive agreement for the immediate exercise of certain outstanding warrants, with expected gross proceeds to the Company of approximately $11.5 million. The combined financings are expected to provide enhanced financial flexibility to support commercial execution, working capital, and general corporate purposes. "This Credit Facility strengthens our ability to continue to execute on the LYMPHIR launch, aligning capital access with commercial performance, and underscoring the confidence that a global investment firm like Avenue Capital has in our commercial trajectory and the long-term potential of LYMPHIR. In parallel, the warrant exercise financing provides additional near-term capital to further support our commercial efforts Collectively, this provides the company with meaningful financial flexibility as we continue to scale our commercial infrastructure, drive adoption of LYMPHIR among treating physicians, and expand patient access to this important therapy for relapsed or refractory cutaneous T-cell lymphoma. We are pleased to have Avenue as a capital partner as we advance our mission to improve outcomes for patients with limited treatment options," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharmaceuticals."Citius Oncology has a differentiated, FDA-approved therapy with a targeted commercial opportunity. We are excited to support the Citius team as they execute on their commercialization strategy and work to realize the full value of their first FDA-approved asset," said Chad Norman, Senior Portfolio Manager of Avenue Capital Group.H.C. Wainwright & Co. is acting as the exclusive origination, structuring and placement agent to Citius Oncology for the financings.Financings SummaryThe Credit Facility has a term of 3.5 years and includes an initial tranche of $10 million, to be fully funded at closing, plus two additional tranches of up to an aggregate of $15 million, subject to achievement of predefined revenue milestones and liquidity conditions. The Company has agreed to issue to Avenue warrants to purchase up to 11,111,111 shares of the Company's common stock, at an exercise price of $0.90 per share, exercisable for a period of five years following the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. The Company will also issue to Avenue warrants to purchase shares of common stock equal to 10% of the amount funded in each future tranche, divided by the exercise price of $0.90 per share. Additionally, Avenue will have the right, at any time while any loan is outstanding, to convert up to $4.0 million of the outstanding principal under the credit facility into shares of the Company's common stock at a price per share equal to 120% of the exercise price of the warrant, subject to certain terms and conditions, including beneficial ownership limitations.Concurrently, the Company entered into definitive agreements with a single healthcare-focused institutional investor for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 12,777,778 shares of common stock, originally issued in July 2025, September 2025, and December 2025, at a reduced exercise price of $0.90 per share, with expected gross proceeds to the Company of approximately $11.5 million prior to deduction of placement agent fees and other offering expenses. In consideration for the immediate exercise of these warrants for cash, the Company will issue new unregistered warrants to purchase up to 25,555,556 shares of common stock. The new warrants will have an exercise price of $0.90 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the new warrants and will expire five years after the later of (i) the date of stockholder approval and (ii) the effective date of the Resale Registration Statement (as defined below). The new warrant offering is expected to close on or about May 6, 2026, subject to satisfaction of customary closing conditions.The Company intends to use the net proceeds from the financings primarily to fund ongoing LYMPHIR commercialization efforts such as sales force expansion, market access initiatives, medical affairs activities, and manufacturing supply chain support, with the remainder to be used for working capital and general corporate purposes.Warrant Offering DisclosureThe new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants (the "Resale Registration Statement").The Company also has agreed to amend certain existing warrants to purchase up to an aggregate of 15,697,024 shares of the Company's common stock that were previously issued to the investor in December 2025, with an exercise price of $1.09 per share, effective upon the closing of the offering, such that the amended warrants will have a reduced exercise price of $0.90 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years after the date of stockholder approval.This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.About LYMPHIR® (denileukin diftitox-cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. The Company believes the addressable U.S. market exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.About Avenue Capital GroupAvenue Capital Group is a global investment firm founded in 1995 and headquartered in New York, with offices across the United States, Europe, Asia, and Abu Dhabi. The firm manages assets estimated at approximately $9.8 billion and is primarily focused on specialty lending, opportunistic credit, and other special situations investments. The Avenue Growth Lending strategy seeks to provide creative financing solutions to high-growth, publicly traded and venture capital-backed technology and life science companies, focusing generally on companies within the underserved segment of the market created by the widening financing gap between commercial banks and larger debt funds. For more information, please visit www.avenuecapital.com.Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price, and include all statements related to the closing and intended use of net proceeds from the offerings. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; the availability of future tranches under the Credit Facility and our ability to conduct future financings; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to regain compliance with Nasdaq's continued listing standards; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.Investor Contact:
Ilanit Allen
ir @crsrs-6677 x113Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-secures-up-to-36-5-million-in-debt-and-equity-capital-to-accelerate-lymphir-commercialization-302763264.htmlSOURCE Citius Oncology, Inc. Original: Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Citius Oncology Ships First International Order of LYMPHIR™ to EuropeApril 29, 2026 8:00 AM
PR Newswire (US)

Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional partners through Named Patient Programs in specific international marketsCRANFORD, N.J., April 29, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made available to eligible patients through Named Patient Programs (NPPs) in accordance with local regulations in each country.







The initiation of European distribution represents a strategic step in the Company's broader effort to extend access to LYMPHIR for patients with limited treatment options, while continuing to prioritize disciplined and targeted market entry."Reaching this milestone underscores our commitment to ensuring that patients in need can access LYMPHIR beyond the United States," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. "Through our distribution partners, we are enabling physicians to request LYMPHIR for appropriate patients via established Named Patient Programs, providing a pathway to treatment where approved alternatives may be limited. Importantly, this progress complements the strong early foundation we are building in the U.S., where we continue to see encouraging adoption across key treatment centers."In the United States, Citius Oncology continues to execute its commercial launch strategy, with ongoing progress in formulary access, expanding payer coverage, and increasing engagement across both academic and community oncology settings. The Company remains focused on supporting physician education and facilitating patient access as LYMPHIR becomes integrated into clinical practice.LYMPHIR was approved by the U.S. Food and Drug Administration in August 2024 for the treatment of adult patients with Stage I–III relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, and was commercially launched in the United States in December 2025.LYMPHIR does not have marketing authorization from the European Medicines Agency in Europe or other countries outside the United States. Access is being provided solely through Named Patient Programs in accordance with applicable local laws and regulations.About LYMPHIR™ (denileukin diftitox-cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to secure and maintain strategic partnerships and expand international access to LYMPHIR; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability to maintain Nasdaq's continued listing standards; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.LYMPHIR™ (denileukin diftitox-cxdl)INDICATIONLYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.IMPORTANT SAFETY INFORMATION BOXED WARNING: CAPILLARY LEAK SYNDROMECapillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.WARNINGS AND PRECAUTIONS Capillary Leak SyndromeLYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin

No dollar figures except 400 million and growing. Still a 15 dollar stock at .60, lots of upside.

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentMarch 31, 2026 9:11 AM
PR Newswire (US)

Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integrationCRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided a commercial update on the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl) for the treatment of cutaneous T-cell lymphoma (CTCL), highlighting continued adoption across leading oncology centers, broad payer coverage progress, and advancing investigator-led clinical studies.







"We are encouraged by the early commercial indicators for LYMPHIR, including the pace of formulary adoption, breadth of payer coverage, and increasing repeat orders from leading oncology centers," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. "As our commercial organization continues to scale and institutions complete formulary inclusion, we expect continued expansion in prescribing activity, including into community settings. Together with further clinical validation through ongoing investigator-led studies, these trends support LYMPHIR's potential not only for continued integration in the CTCL treatment landscape, but also its potential as a part of a combination immunotherapy regimen in other cancers."Key Early Launch Metrics:Sequential growth in orders from target institutions since launch, with initial accounts already placing repeat orders, indicating early prescribing continuity;Strong institutional uptake, with 83% of target accounts having added or actively progressing LYMPHIR through formulary review;Broad and expanding market access with ~135 health plans, representing ~80% of covered lives, secured and reimbursement systems established;No reported reimbursement denials or prior authorization barriers;Increasing demand for in-services and clinical education;Initial penetration into community infusion centers underway with patients beginning to transition from larger cancer centers; and,Commercial buildout proceeding, with field team onboarding in the coming month and broader field expansion in progress with our contracted sales organization.Commercial Execution Advancing with Expanding Market Access and Field DeploymentCommercial execution continues to advance with the onboarding of field teams, targeted deployment of medical education and digital campaigns, attendance at major medical meetings and increasing interaction with physicians, pharmacy stakeholders, and community centers to support the finalization of order sets and initiate patient treatment, which typically precedes broader patient start acceleration following formulary inclusion.Commercial supply remains well positioned to support anticipated U.S. demand, and international expansion is underway through executed distribution agreements across Europe and the Middle East.Clinical Development Expands Through Leading Academic CollaborationsIn parallel, Citius Oncology is advancing LYMPHIR's clinical development through collaborations with leading academic centers to further evaluate its potential across broader oncology settings. At the University of Minnesota, an investigator-sponsored study is evaluating LYMPHIR prior to CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma, with positive topline data presented at the ASTCT 2026 Annual Meeting and additional analyses underway. At UPMC, a Phase I study evaluating LYMPHIR in combination with pembrolizumab in solid tumors has been completed, with positive topline results submitted for presentation at an upcoming oncology conference. Discussions are ongoing regarding next-stage development. These efforts support a broader strategy to evaluate LYMPHIR as a potential combination therapy across immuno-oncology settings.Together, these commercial and clinical developments support a disciplined launch trajectory and provide a solid foundation for continued adoption of LYMPHIR.About LYMPHIR™ (denileukin diftitox-cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability to maintain Nasdaq's continued listing standards; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.LYMPHIR™ (denileukin diftitox-cxdl)INDICATIONLYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.IMPORTANT SAFETY INFORMATION BOXED WARNING: CAPILLARY LEAK SYNDROMECapillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.WARNINGS AND PRECAUTIONS Capillary Leak SyndromeLYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin

A lot of there news isn't showing up in some outlets, not sure why. Might do better if it did.

Good buying opportunity here,, bollinger at bottom, obviously leveling and ready to turn up, a flippers dream of 10pct gain over a short period.

Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic CancersMarch 10, 2026 8:47 AM
PR Newswire (US)

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacyTopline data of University of Pittsburgh-led trial to be presented at an upcoming international cancer conference later this yearCRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator-initiated Phase?1 clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory (Treg) cell depletion activity of LYMPHIR™ (denileukin diftitox-cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.







Patients with relapsed or refractory gynecological cancer have poor prognoses and very limited treatment options. This dose-escalation Phase 1 non-chemotherapy based clinical study aimed to establish a recommended dose of LYMPHIR in combination with pembrolizumab for a Phase 2 study. In 25 evaluable patients, no unexpected safety signals or serious immune-related adverse events were observed at any dose level."We are encouraged by the favorable safety profile and sustained disease control observed in this heavily pretreated patient population. Evidence from the study suggests augmented anti-tumor activity when LYMPHIR is combined with KEYTRUDA and warrants further exploration in Phase?2 settings," stated Dr. Myron Czuczman, Executive Vice President and Chief Medical Officer of Citius Oncology and Citius Pharma.The trial explored efficacy and demonstrated a 24?% objective response rate (ORR) and a 48?% clinical benefit rate (CBR, defined as complete response, partial response and/or stable disease for six months or greater) among 21 evaluable patients. Full safety and clinical efficacy results are expected to be presented at an international cancer conference later this year."The efficacy signal shown by this combination is incredibly exciting considering the minimal impact immuno-oncology has made in ovarian cancer thus far. If these findings are confirmed in subsequent studies, we may have a transformational therapy on our hands," said Dr. Alexander Olawaiye, principal investigator of the study.About the StudyThis open-label, dose-escalation, investigator-initiated Phase?1 study (NCT05200559), led by Dr. Alexander B Olawaiye at UPMC Magee-Women's Hospital, enrolled patients with recurrent or metastatic solid tumors who had received at least one prior line of therapy. LYMPHIR was administered intravenously on Days?1–3 of each 21-day cycle at escalating doses (3, 6, 9, and 12 mcg/kg), along with pembrolizumab (200?mg IV) on Day?1. Patients who completed eight cycles of combination therapy were continued on pembrolizumab monotherapy until disease progression.The use of LYMPHIR in this study was investigational and outside of its FDA-approved indication. The Phase 1 study was not designed or powered to evaluate clinical efficacy, and no conclusions can be drawn regarding comparative effectiveness or long-term outcomes.About Gynecologic CancersRecurrent or metastatic ovarian and endometrial cancers are two of the most common gynecologic malignancies in the United States. Endometrial cancer is the most frequently diagnosed gynecologic cancer, with an estimated 70,000 new cases expected in 20261, while ovarian cancer remains the deadliest with approximately 12,700 deaths per year (51.6% 5 year survival) and approximately 20,000 new diagnoses each year2. These cancers are often detected at advanced stages, and although many patients initially respond to platinum-based chemotherapy, most experience relapse and develop resistance. Survival rates in the recurrent setting remain poor, and responses to current immunotherapies such as PD-1 inhibitors are limited, highlighting a significant unmet need for novel treatment approaches. LYMPHIR's transient depletion of regulatory T-cells may enhance anti-tumor immune responses and help overcome immunotherapy resistance in these difficult-to-treat tumors.About LYMPHIR™ (denileukin diftitox-cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; early-stage clinical data may not be predictive of results from larger or later-stage studies; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to maintain Nasdaq's continued listing standards; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.REFERENCES:American Cancer Society. Cancer Facts & Figures 2026 (projected). Atlanta: American Cancer Society; 2026. https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.htmlNational Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Uterine and Ovarian Cancer. https://seer.cancer.gov/statfacts/html/ovary.htmlKEYTRUDA® is a registered trademark of Merck & Co., Inc.LYMPHIR™ (denileukin diftitox-cxdl)INDICATIONLYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.IMPORTANT SAFETY INFORMATION BOXED WARNING: CAPILLARY LEAK SYNDROMECapillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.WARNINGS AND PRECAUTIONS Capillary Leak SyndromeLYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin

F/Y/I

Finally, Mazur may give some updated guidence on Lymphir sales.Now the key question becomes: How does Citius scale from its initial oncology launch to deliver meaningful revenue visibility in 2026, and beyond?

Join Jason Kolbert, Head of Research at D. Boral Capital, for a live webinar with Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals, to discuss:

CEO Leonard Mazur will speak at a webinar hosted by D. Boral Capital. Scheduled March 11 at 11:00am

Early LYMPHIR launch traction and physician adoption
Commercial execution strategy in a rare oncology market
Balance sheet positioning, including recent $3.8M non-dilutive funding
Revenue ramp expectations into 2026 and 2027
The role of Mino-Lok and Halo-Lido in portfolio diversification
Strategic priorities as Citius transitions into a multi-asset commercial company

https://dboralcapital.com/citius-pharmaceutical-live-discussion-with-ceo-leonard-mazur/

Volume up today, looks like people are loading up. Rose from 700k to 4 million. I bought a few more.

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell LymphomaMarch 4, 2026 9:15 AM
PR Newswire (US)

Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was well-tolerated with no dose-limiting toxicities observedCRANFORD, N.J., March 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox-cxdl) administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial was conducted by lead investigator, Dr. Veronika Bachanova, at the University of Minnesota and City of Hope. Full results were presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings1.







The Phase 1 trial was designed to augment the lymphodepletion regimen prior to CAR-T infusion through the administration of LYMPHIR to potentially improve the anti-tumor activity of CAR-T therapies. LYMPHIR, an engineered fusion toxin that preferentially binds to the IL-2 receptor expressed on regulatory T-cells (Tregs), is currently FDA-approved and commercially available for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after one prior systemic therapy.  "Enhancing Treg depletion prior to CAR-T infusion with LYMPHIR represents a promising immunomodulatory strategy in patients with high-risk DLBCL, and these Phase 1 data provide an encouraging signal of the potential to enhance current CAR-T regimens," said Dr. Myron Czuczman, Executive Vice President and Chief Medical Officer of Citius Oncology and Citius Pharma. "These positive data support our broader strategy of exploring LYMPHIR's modulatory effect on Tregs in combination with other approved therapies to potentially enhance the body's own immune system to fight cancerous tumors," he added.Topline Results & Study DesignAll patients (n=14) completed treatment and proceeded to CAR-T infusion;LYMPHIR was well tolerated, with no dose-limiting toxicities observed;No Grade ≥3 LYMPHIR-related immune adverse events or infusion reactions were reported; and,Data demonstrated effective Treg depletion, and promising efficacy signals of enhanced standard lymphodepletion with the use of Treg-targeting LYMPHIR.The Phase 1, open-label, dose-escalation study (NCT04855253), enrolled 14 patients with relapsed or refractory DLBCL exhibiting poor prognostic features, including double/triple hit genetics, primary refractory disease, and extranodal involvement. Participants received one dose of LYMPHIR (E7777) at 5, 7, or 9 µg/kg followed by low dose chemotherapy prior to standard commercial CD19-directed CAR-T cell therapy. All patients received an infusion of one of the following FDA-approved, commercially manufactured CAR-T products: axicabtagene ciloleucel (Yescarta®; Kite Pharma/Gilead Sciences), lisocabtagene maraleucel (Breyanzi®; Bristol Myers Squibb), or tisagenlecleucel (Kymriah®; Novartis).The use of LYMPHIR in this study was investigational and outside of its FDA-approved indication. The Phase 1 study was not designed or powered to evaluate clinical efficacy, and no conclusions can be drawn regarding comparative effectiveness or long-term outcomes.Key Findings from the Phase 1 TrialOverall response rate (ORR) was 86% at one?month, including 57% complete responses (CR) and 29% partial responses (PR);One-year progression-free survival (PFS) was 77% (95% CI: 43–92%);One-year overall survival (OS) was 84% (95% CI: 49–96%);A single LYMPHIR dose resulted in depletion of circulating Tregs in all but one patient;Median reduction of 24?Tregs/µL (range 8–65);Treg nadir was observed 24 hours post-LYMPHIR;LYMPHIR was well tolerated with no dose-limiting toxicities (DLTs) observed up to 9?µg/kg; and,Reported adverse events included manageable Grade?1–2 capillary leak syndrome, fever, and transient liver enzyme elevations; Grade?3 cytopenias were consistent with expected lymphodepletion. CAR-T related cytokine release syndrome (CRS) occurred in 43% of patients (all Grade?1/2), and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 21% (primarily low grade)."In this high-risk population, LYMPHIR showed a favorable safety profile and promising pharmacodynamic effects when administered prior to CAR-T therapies. This data sets the stage for a larger study to assess its potential to enhance CAR-T efficacy through longer duration of LYMPHIR use," said Dr. Veronika Bachanova, Principal Investigator and Professor of Medicine at the University of Minnesota.Dr. Bachanova presented the topline data at the 2026 Tandem Meetings | ASTCT® CIBMTR®.Title: E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T for High-Risk LBCL
Presentation ID: 677608
Abstract ID: 296369About Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30%–40% of newly diagnosed cases in the United States. DLBCL is an aggressive and rapidly growing cancer of B lymphocytes, a type of white blood cell responsible for producing antibodies. While frontline chemoimmunotherapy regimens such as R-CHOP can be curative for many patients, up to 40% experience relapse or refractory disease. High-risk features are associated with poor outcomes and limited responses to standard therapies, including CAR-T cell therapy. Novel strategies that modulate the tumor microenvironment, such as transient regulatory T-cell depletion, are under investigation to improve treatment efficacy and long-term remission rates in this difficult-to-treat population.About LYMPHIR™ (denileukin diftitox-cxdl)LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those from our existing and any new pipeline assets;  early-stage clinical data may not be predictive of results from larger or later-stage studies;, our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to maintain Nasdaq's continued listing standards; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.REFERENCES:Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) & the Center for International Blood and Marrow Transplant Research (CIBMTR®)Yescarta® is a registered trademark of Kite Pharma, Inc., a Gilead company.Breyanzi® is a registered trademark of Bristol Myers Squibb.Kymriah® is a registered trademark of Novartis.LYMPHIR™ (denileukin diftitox-cxdl)INDICATIONLYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.IMPORTANT SAFETY INFORMATION BOXED WARNING: CAPILLARY LEAK SYNDROMECapillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.WARNINGS AND PRECAUTIONS Capillary Leak SyndromeLYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin

Pretty crazy this hasn't made a big move, low float too. Just sitting last two days. Can wait.

The Analysts are predicting $40M for fiscal 2026 (ending on 9/20/2026) but they don't expect earnings to be above zero for the fiscal year.....

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctor/citius-oncology/future

10 mil would make 40 mil for a year, likely profitable. Could be lower and still go up 300 pct.

I was thinking $10M for the whole 2nd quarter, ending on 03/31/2026, but that might be too optimistic, because that would make it a PROFITABLE QUARTER and the all-knowing analysts aren't predicting a profit in Q2.

Q1 had $4M in stock-based compensation for the insiders, to reward them for the launch. That's not going to happen again in Q2.

2026 might be very very good for CTOR.

Wonder how much they made after December numbers? 10 mil ?

I can be pretty dumb

I think you meant to say $5 not 5 cents. It is $1.14 now,

It happens to everyone.

5 cents by June, very possible now. Stocks go down cause people are buying in, then it pops. Maybe next week it starts. Peeps have to find it first.

I would agree.

When a company states the company initiated or officially started, began, or launched a particular activity, process, project, or action as of that specified date doesn't mean they have sold anything..

I always maintain silence from emerging biotechs and penny stocks usually mean things aren't going as expected, but it is not always the case.

I think they started selling later than expected which is why they missed guidance, once selling they did well. If approved in europe this would fly.

At this point, investors do not seem to be impressed. Possibly because they were short of expectations which may also be the reason the CEO was quiet.

Could be a delayed reaction, Just have to wait and see during normal trading hours.

Ed will probably be upset,

LMAO!

Why in the world would i be upset?

So funny!

$3.9M revenue for one month of sales. At this rate, they will be profitable next quarter. Won't THAT be something.

Apparently, analysts were guessing $4.3M, so on paper they missed the analyst estimate of .04 loss -- it was .06 loss per share.

Ed will probably be upset, but $3.9M revenues for one month are fine with me.

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™February 13, 2026 8:00 AM
PR Newswire (US)

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial resultsCRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR)."I am thrilled to report that we have successfully transitioned to a revenue generating company following Citius Oncology's December 2025 launch of LYMPHIR. We recorded $3.9 million in revenue during the quarter, reflecting the initial sales at Citius Oncology's nationwide network of distributors. This milestone is the result of years of focused execution designed to translate innovation into tangible value for the cutaneous T-cell community and Citius stakeholders alike. I congratulate the entire Citius team on an outstanding effort to bring LYMPHIR to market," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma."While we are still in the early stages of the launch, we expect momentum to build as we continue to stand up the full commercial organization and more fully deploy our technology-driven platform to expand patient access and drive market penetration. Looking ahead, we see multiple avenues for growth, including encouraging early signals from investigator-initiated studies, opportunities to expand access in international markets, and the potential to build a durable oncology franchise. Most importantly, LYMPHIR now offers patients living with cutaneous T-cell lymphoma a meaningful new treatment option and a more hopeful future," added Mazur."We remain committed to financial stewardship to sustain this momentum, and focused execution to advance our late-stage pipeline, which includes Mino-Lok and Halo-Lido. Our goal remains to serve our community with first-in-class critical care products, and in so doing maximize long-term shareholder value," concluded Mazur.Business Highlights and Subsequent DevelopmentsCommercial inflection achieved through majority-owned subsidiary: Citius Oncology successfully launched LYMPHIR™ (denileukin diftitox-cxdl) in the U.S. in December 2025 for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy;Early physician adoption underway: Initial specialty distributor sales were completed nationwide, enabling product availability across U.S. treatment centers. Patients have begun receiving LYMPHIR at leading cancer centers;Commercial execution supported by technology: Citius Oncology deployed an AI-enabled commercial platform to support targeted physician engagement and efficient penetration of a highly concentrated prescriber base in this rare oncology market;International patient access advancing: Agreements have been negotiated with regional partners to enable patient access to LYMPHIR utilizing Named Patient Programs (NPPs) where permitted in territories throughout European and the Middle East;Continued support of promising upside opportunities for LYMPHIR: Preliminary topline data from two investigator-initiated Phase I combination studies evaluating the potential to expand clinical utility and future label expansion opportunities. include:use in combination with pembrolizumab in patients with recurrent solid tumors;incorporation as part of lymphodepletion regimens prior to CAR-T therapy;Late-stage pipeline progress maintained: Citius Pharma continues to advance Mino-Lok®, an antibiotic lock solution to salvage catheters when treating catheter-related bloodstream infections, and Halo-Lido (CITI-002), a topical prescription formulation for hemorrhoids. The Company remains engaged with the FDA regarding both programs.First Quarter 2026 Financial HighlightsCash and cash equivalents totaled $7.7 million as of December 31, 2025;Generated net proceeds of approximately $20.9 million from equity financings during the quarter, including capital raised at both Citius Pharma and Citius Oncology;Consolidated revenue was $3.9 million, reflecting initial U.S. sales of LYMPHIR at Citius Oncology;Research and development expenses were $1.6 million, compared to $2.1 million in the prior-year period, reflecting reduced clinical development activity;General and administrative expenses totaled $5.7 million, compared to $5.4 million in the prior-year period;Stock-based compensation expense totaled $4.3 million, compared to $2.5 million in the prior-year period; and,Net loss applicable to common stockholders was $8.2 million, or $(0.41) per share, compared to a net loss of $9.8 million, or $(1.30) per share, in the prior-year period.About Citius Pharmaceuticals, Inc. 
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 74.8% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to maintain Nasdaq's continued listing standards; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.Investor Contact:
Ilanit Allen
ir @crsrs-6677 x113Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)


December 31,

September 30,

2025

2025ASSETS




Current Assets:




Cash and cash equivalents
$7,721,393

$4,252,290Accounts receivable, net of allowances

4,049,111


-Inventory

22,639,342


22,286,693Prepaid expenses

3,535,287


1,395,490Total Current Assets

37,945,133


27,934,473







Operating lease right-of-use asset, net

835,177


818,694







Deposits

38,062


38,062In-process research and development, net of accumulated amortization

92,226,562


92,800,000Goodwill

9,346,796


9,346,796Total Other Assets

101,611,420


102,184,858







Total Assets
$140,391,730

$130,938,025







LIABILITIES AND STOCKHOLDERS' EQUITY






Current Liabilities:






Accounts payable
$11,021,412

$13,693,692License payable

18,250,000


22,650,000Accrued expenses

4,693,307


4,190,253Accrued compensation

3,094,395


3,292,447Note payable

1,000,000


1,000,000Operating lease liability

148,006


88,348Total Current Liabilities

38,207,120


44,914,740







Deferred tax liability

8,035,000


7,770,760Operating lease liability – noncurrent

681,640


724,925Total Liabilities

46,923,760


53,410,425







Commitments and Contingencies














Stockholders' Equity:






Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued
     and outstanding

-


-Common stock - $0.001 par value; 250,000,000 shares authorized; 22,376,427 and
     18,067,744 shares issued and outstanding at December 31, 2025 and September
     30, 2025, respectively

22,376


18,068Additional paid-in capital

326,960,700


306,336,239Accumulated deficit

(247,024,914)


(238,804,129)Total Citius Pharmaceuticals, Inc. Stockholders' Equity

79,958,162


67,550,178Non-controlling interest

13,509,808


9,977,422Total Equity

93,467,970


77,527,600







Total Liabilities and Equity
$140,391,730

$130,938,025 CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024(Unaudited)


Three Months Ended

December 31,

December 31,

2025

2024Revenue
$3,944,111


—Cost of revenues

(789,208)


—Gross Profit

3,154,903


—







Operating Expenses






Research and development

1,599,719


2,127,038Amortization of in-process research and development

573,438


—General and administrative

5,720,727


5,387,752Stock-based compensation – general and administrative

4,280,227


2,524,824Total Operating Expenses

12,174,111


10,039,614Operating Loss

(9,019,208)


(10,039,614)Other Income (Expense)






Interest income

45,097


22,608Interest expense

(155,538)


—Total Other Income (Expense)

(110,441)


22,608Loss before Income Taxes

(9,129,649)


(10,017,006)Income tax expense

264,240


264,240Net Loss

(9,393,889)


(10,281,246)Net loss attributable to non-controlling interest

1,173,104


513,000Net loss applicable to common stockholders
$(8,220,785)

$(9,768,246)







Net Loss Per Share - Basic and Diluted
$(0.38)

$(1.30)







Weighted Average Common Shares Outstanding






Basic and diluted (include pre-funded warrants from the October
2025 offering)

21,495,274


7,492,460 CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024(Unaudited)


2025

2024Cash Flows From Operating Activities:




Net loss
$(9,393,889)

$(10,281,246)Adjustments to reconcile net loss to net cash used in operating activities:






Stock-based compensation expense

4,280,227


2,524,824Issuance of common stock for services

107,510


—Issuance of common stock warrant

68,597


—Amortization of in-process research and development

573,438


—Amortization (accretion) of operating lease right-of-use asset

(16,483)


54,835Deferred income tax expense

264,240


264,240Changes in operating assets and liabilities:






Accounts receivable, net of allowances

(4,049,111)


—Inventory

(352,649)


(6,112,603)Prepaid expenses

(2,139,797)


(145,739)Accounts payable

(2,672,280)


2,436,909Accrued expenses

503,054


6,225,151Accrued compensation

(198,052)


366,073Operating lease liability

16,373


(58,296)Net Cash Used In Operating Activities

(13,008,822)


(4,725,852)







Cash Flows From Investing Activities:






License fee payments

(4,400,000)


—Net Cash Used in Investing Activities

(4,400,000)


—







Cash Flows From Financing Activities:






Net proceeds from common stock offerings

20,877,925


2,574,051Net Cash Provided By Financing Activities

20,877,925


2,574,051







Net Change in Cash and Cash Equivalents

3,469,103


(2,151,801)Cash and Cash Equivalents - Beginning of Period

4,252,290


3,251,880Cash and Cash Equivalents - End of Period
$7,721,393

$1,100,079Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:






Interest paid
$14,460

$—





View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-announces-first-reported-revenue-following-successful-launch-of-lymphir-302687092.htmlSOURCE Citius Pharmaceuticals, Inc.

Original: Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™February 13, 2026 8:00 AM
PR Newswire (US)

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial resultsCRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update.







"The first quarter of fiscal 2026 marked a pivotal inflection point for Citius Oncology with the successful U.S. commercial launch of LYMPHIR and the Company's first reported revenue," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma. "This transition from a development-stage organization to a commercial oncology company reflects years of deliberate preparation and coordination across our clinical, manufacturing, distribution, and commercial infrastructure.""With initial distributor sales complete nationwide, we are now focused on accelerating physician adoption and expanding patient access. Since the start of calendar 2026, physicians have begun to initiate patients on LYMPHIR, and our formulary review efforts are progressing as planned. We are preparing to expand our field presence to support a highly concentrated prescriber base in this rare cancer setting, supported by an advanced AI-enabled commercial platform designed to drive efficient market penetration," added Mazur."As LYMPHIR is now broadly available, we remain focused on execution, capital management, and evaluating strategic opportunities that we believe can meaningfully enhance long-term shareholder value," concluded Mazur.Business Highlights and Subsequent DevelopmentsInitiated U.S. commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) in December 2025, establishing Citius Oncology as a commercial-stage oncology company with an FDA-approved IL-2 receptor-directed immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy;Established nationwide specialty distribution infrastructure, completing initial distributor sales to ensure immediate product availability across U.S. treatment centers and support rapid physician adoption;Initiated treatment of CTCL patients at leading U.S. cancer centers;Deployed an AI-enabled commercial platform to drive targeted physician engagement, optimize field execution, and efficiently penetrate a highly concentrated prescriber base; and,Advanced international access strategy outside the U.S. through regional distribution partners and Named Patient Programs (NPPs) in key European and Middle Eastern markets, enabling patient access where permitted by local law without constituting commercial approval;Continued to expand long-term value optionality through investigator-initiated Phase I combination studies evaluating LYMPHIR:in combination with pembrolizumab in patients with recurrent solid tumors; and,as part of lymphodepletion regimens prior to CAR-T therapy, supporting potential future label expansion opportunities.First Quarter 2026 Financial HighlightsCash and cash equivalents totaled $7.3 million as of December 31, 2025;Completed a registered offering in December 2025, generating net proceeds of approximately $15.1 million;Revenue of $3.9 million during the quarter ended December 31, 2025 reflects sales related to the launch of LYMPHIR;Research and development expenses were $1.0 million, compared to $1.3 million in the prior-year period, reflecting reduced clinical development activity;General and administrative expenses were $2.9 million, compared to $3.3 million in the prior-year period;Stock-based compensation expense totaled $4.0 million, primarily related to equity grants issued in September 2025, compared to $1.8 million in the prior-year period; and,Net loss for the quarter was $5.5 million, or $(0.06) per share, compared to a net loss of $6.7 million, or $(0.09) per share, for the prior-year period.About Citius Oncology, Inc.Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.About Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 75% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our ability to maintain Nasdaq's continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.Investor Contact:
Ilanit Allen
ir @crsrs-6677 x113Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)


December 31,
2025

September 30,
2025Current Assets:




Cash and cash equivalents
$7,295,451

$3,924,908Accounts receivable, net of allowances

4,049,111


—Inventory

22,639,342


22,286,693Prepaid expenses

3,162,940


1,331,280Total Current Assets

37,146,844


27,542,881







Other Assets:






In-process research and development, net of accumulated amortization

72,826,562


73,400,000Total Other Assets

72,826,562


73,400,000







Total Assets
$109,973,406

$100,942,881LIABILITIES AND STOCKHOLDERS' EQUITY






Current Liabilities:






Accounts payable
$10,446,900

$13,234,684License payable

18,250,000


22,650,000Accrued expenses

4,518,916


4,093,124Due to related party

11,494,578


9,513,771Total Current Liabilities

44,710,394


49,491,579







Deferred tax liability

3,049,200


2,784,960Note payable to related party

3,800,111


3,800,111Total Liabilities

51,559,705


56,076,650Stockholders' Equity:






Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued
     and outstanding

—


—Common stock - $0.0001 par value; 400,000,000 shares authorized at December 31,
     2025 and September 30, 2025; 84,797,846 and 83,513,442 shares issued and
     outstanding at December 31, 2025 and September 30, 2025, respectively

8,480


8,351Additional paid-in capital

127,979,246


108,897,836Accumulated deficit

(69,574,025)


(64,039,956)Total Stockholders' Equity

58,413,701


44,866,231Total Liabilities and Stockholders' Equity
$109,973,406

$100,942,881 CITIUS ONCOLOGY, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024(Unaudited)


Three Months Ended

December
31,

December
31,

2025

2024   Revenue
$3,944,111

$—   Cost of revenues

(789,208)


—   Gross Profit

3,154,903


—







Operating Expenses






Research and development

1,018,352


1,264,508Amortization of in-process research and development

573,438


—General and administrative

2,859,339


3,321,979Stock-based compensation – general and administrative

3,956,050


1,808,478Total Operating Expenses

8,407,179


6,394,965







Operating Loss

(5,252,276)


(6,394,965)







Other Income (Expense)






Interest income

28,288


—Interest expense

(45,841)


—Total Other Income (Expense), Net

(17,553)


—Loss before Income Taxes

(5,269,829)


(6,394,965)Income tax expense

264,240


264,240







Net Loss
$(5,534,069)

$(6,659,205)







Net Loss Per Share - Basic and Diluted
$(0.06)

$(0.09)







Weighted Average Common Shares Outstanding






   Basic and diluted (includes pre-funded warrants from the December 2025 offering)           

87,462,385


71,552,402 CITIUS ONCOLOGY, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024(Unaudited)


2025

2024   Cash Flows From Operating Activities:




Net loss
$(5,534,069)

$(6,659,205)Adjustments to reconcile net loss to net cash provided by operating activities:






      Stock-based compensation expense

3,956,050


1,808,478      Amortization of in-process research and development

573,438


-      Deferred income tax expense

264,240


264,240   Changes in operating assets and liabilities:






      Accounts receivable, net of allowances

(4,049,111)


-      Inventory

(352,649)


(6,112,603)      Prepaid expenses

(1,831,660)


-      Accounts payable

(2,787,784)


2,162,955      Accrued expenses

425,792


6,228,612      Due to related party

1,980,807


2,307,523Net Cash (Used In) Provided By Operating Activities

(7,354,946)


-Cash Flows From Investing Activities






    License payments

(4,400,000)


-Net Cash Used In Investing Activities

(4,400,000)


-Cash Flows From Financing Activities






    Net proceeds from issuance of common stock

15,125,489


-Net Cash Provided by Financing Activities

15,125,489


-Net Change in Cash and Cash Equivalents

3,370,543


-Cash and Cash Equivalents – Beginning of Period

3,924,908


112Cash and Cash Equivalents – End of Period
$7,295,451

$112Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:   






Interest Paid
$14,460

$- 



View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-announces-first-reported-revenue-following-successful-launch-of-lymphir-302687114.htmlSOURCE Citius Oncology, Inc.

Original: Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Murphy's law!

As soon as i post, they release the the Quarterly for 12/31/2025.

https://citiusonc.com/news/news-details/2026/Citius-Oncology-Inc--Announces-First-Reported-Revenue-Following-Successful-Launch-of-LYMPHIR/default.aspx

Just a note:

CTOR 10-Q filing ended Dec 31,25 deadline is Saturday 2/14/26 which is 45 days after the QTR ending date for 12/31/25 for a non-accelerated filer ( (Jan 31 days and Feb 14 days makes it 45 days). However, 2/14/26 is a Sat, so the 10-Q filing deadline is actually Tuesday Feb 17 26, the 1st business day after (2/16/26 is a holiday) If they do not file by the end of today. The 10-Q will report Lymphir's sales (if any) from launch 12/1/25 through Dec 31,25. They may give some 2026 guidance for Lymphir sales.

Citius Oncology inks exclusive European distribution pact with UnipharFebruary 11, 2026 11:07 AM
IH Market News
Citius Oncology Inc. (NASDAQ:CTOR) said it has signed an exclusive agreement with Uniphar to broaden access to LYMPHIR (denileukin diftitox-cxdl) across selected Western and Eastern European markets.Under the terms of the deal, Uniphar will act as the sole distribution partner for LYMPHIR via country-specific managed access programs, where allowed under local regulations. Citius Oncology will provide finished product supply and ongoing support. The therapy is not approved for commercial sale outside the United States and will be made available strictly through managed access programs, which do not represent formal marketing authorization or a commercial launch.The partnership marks the company’s third international distribution arrangement, following earlier agreements covering Southern Europe, the Balkans, Turkey, and the Middle East. Citius Oncology operates as a subsidiary of Citius Pharmaceuticals Inc.“This agreement with Uniphar builds on the momentum of our international expansion efforts and reflects our commitment to partnering with experienced organizations that have deep regional expertise and proven execution capabilities,” said Leonard Mazur, Chairman and CEO of Citius Oncology.LYMPHIR is a targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), indicated for Stage I-III disease after at least one prior systemic treatment. The U.S. Food and Drug Administration approved the therapy in December 2025 for adult patients with relapsed or refractory Stage I-III CTCL who have received at least one prior systemic therapy.Uniphar, based in Dublin, Ireland, is a global healthcare services provider operating in 180 countries and employing more than 3,500 people. The company partners with over 200 multinational pharmaceutical and medical technology firms.Citius Oncology stock price

Original: Citius Oncology inks exclusive European distribution pact with Uniphar

The 10-Q is due Feb 15th by the SEC but will likely be released Friday 2/13.

Analyst estimate for Q1 is -0.04, and for Q2 it's -0.03

Last two quarters:
Q3 2025 estimate -0.15, beat with -0.08
Q4 2025 estimate -0.06, it was -0.06

The US Launch PR was Dec 1st so it will be interesting to see revenues for the first quarter with US sales (the last month of Q1).


CTOR

She's just wobbling around waiting on news or filings. March 23 may be the filing date. No news means no material events to report. I hate waiting.

You're complaining that the company didn't ask for a vote because they already had a majority vote.

Complaining????? LMAO.

NO. Wrong. just stating the facts.

Show me the actual complaint other than stating the facts--I'll wait right here.

You're complaining that the company didn't ask for a vote because they already had a majority vote.

Now you're saying that you don't own this stock and have never owned it. You wouldn't get to vote ANYWAY. So why do you care?

If you're trying to stand up for shareholders out of altruism:

1. Complaining HERE does nothing. Your only audience here is me, pretty much.

2. I am a shareholder and I'm fine with this. Get off my side.

I consider the insider majority ownership to be a good thing. Find something else to bash. "No weekly revenue report" was pretty thin too.

LOL

LMAO.

I have news for you.

I do not own this stock,and have never owned it. Just because i post here doesn't mean i own it.

Unhappy?? Not me. Are you? If you own it you should be.

I am just posting a fact and a thought. Am i not allowed.

Trying to discredit me is laughable. Obvious my opinion was wrong back then DUH!!

That's been true since the inception CTOR. That was true when you were telling us that $2.85 was "the perfect buying opportunity" in post #112.

So why are you unhappy about this now?

Apparently shareholders, other then insiders have no say and Management can do whatever they want.The Executives,Directors, and the parent company hold 74.8% of the outstanding shares.

From the Pre 14c filing yesterday:

The common warrants need shareholder approval before they could be exercised. Since CTXR owns 66m shares, no shareholder vote will be necessary. As majority shareholder, CTXR gives their written consent to allow the common warrants to be exercised. Even if everyone else votes NO, the proposal would still pass.

We are not seeking written consent from any stockholders other than as set forth above, and our other stockholders will not be given an opportunity to vote with respect to the actions taken. All necessary corporate approvals have been obtained, and this Information Statement is furnished solely for the purpose of advising stockholders of the actions taken by the Stockholder Written Consent and giving stockholders advance notice of the actions taken.

"NO VOTE OR OTHER CONSENT OF OUR STOCKHOLDERS IS SOLICITED IN CONNECTION WITH THIS INFORMATION STATEMENT. WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY."


As of the Record Date, 88,275,204 shares of our Common Stock were issued and outstanding. Each share of our Common Stock is entitled to one vote. Pursuant to Section 228 of the DGCL, as outlined above, at least a majority of the voting equity of the Company, or at least 42,398,924 votes, are required to approve the corporate actions by written consent. Our majority stockholder, Citius Pharmaceuticals, Inc. (“Citius Pharma”), who, as of the Record Date, held 66,049,615 shares of Common Stock, representing approximately 74.8% of the voting equity of the Company, has voted in favor of the Warrant Shares Issuance, thereby satisfying the requirement pursuant to the DGCL that at least a majority of the voting equity vote in favor of a corporate action by written consent.

If no revenue in this qtr then safe to say they strung everyone along.

Short is just under 2pct, so short squeeze is possible. Timing is key as to how much she runs.

I think the float is about 18 million -- the "General Public" owns 10.3M and hedge funds own 7.6 million.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctor/citius-oncology/ownership

CTXR is heavily shorted, for good reason. I hope those shorts are also shorting CTOR. We could get a short squeeze here.

Best of luck to all, except to the shorts, LOL -- I wish horrible luck to you shorties.

Float 11mil, industry avg 36mil,

You have to wait 3 months for filings, so retail is behind reality, even then companies can have 3 years to make corrections. Press releases are forward looking and don't match reality.

Whatt????

Of course a retail investor knows how the company is doing. They know this by PR's that are issued by the company that has some kind of guidence.

An emerging Bio tech with it's first product would scream from the mountain to is the product is selling well and well recieved by the medical field. Of couse they wouldn't give numbers until the financials, but at least they have guidence.

Cannot see how you do not understand that.

Not going to respond on this anymore topic since it is nonsense. CTOR at this point is not a proven company that has a product that is in demand.Just reality.

No retail investor can know how a company is really doing. So I don't care about knowing what I cant know. All your facts are worth little. 121 million os is relatively small, pretty reasonable.

Come on. Believe mean i know all about floats.

A small float is only good if there is a demand for the stock. There isn't any in CTOR. The whole idea of buying a stock is for growth. My point was and is shareholders are in the dark, since the CEO sys nothing. So righ now this based on hope. Does anyone know how they are doing? The answer is NO.

Secondly after all of the shares in the last offifering eventually are sold there will be close to 121 million O/S.Surely moe down the road will be issued.

Anytime someone says anything that is not favorable to a penny stock, some always defend it.

Any stock can do well, but until CTOR shows anything about about growth then it sould be considered. Yeah i know get in before the blastoff, the usual nonsense.

The CEO has a very bad track record.

If some investors in an established company that is doing well only 10% they may get hurt, but invest in company that has not establised itself or has sold anything yet 90% of the time they will get hurt.

Float is the most important fact for any stock. Sales mean nothing if the float is outrageous. This stock is float locked pretty much. It can go up. Float locked stocks can rise on small revenues because the share structure is the commodity. I'm not saying buy now. I'm saying this has a time.